Skip to main content

Table 2 Association of PD-L1 staining with clinicopathologic factors in all patients with neoadjuvant chemotherapy

From: Comparison of three scoring methods using the FDA-approved 22C3 immunohistochemistry assay to evaluate PD-L1 expression in breast cancer and their association with clinicopathologic factors

 

TC

TCIC

IC

sTIL level

Factors

Negative

Positive

Fisher

Negative

Positive

Fisher

Negative

Positive

Fisher

Low

High

Fisher

N (%)

N (%)

P value

N (%)

N (%)

P value

N (%)

N (%)

P value

N (%)

N (%)

P value

Age

[N = 141]

 

[N = 131]

 

[N = 131]

 

[N = 145]

 

 < 50 years

50 (94)

3 (6)

0.535

45 (88)

6 (12)

0.1651

47 (92)

4 (8)

0.1257

41 (73)

15 (27)

0.557

 ≥ 50 years

79 (90)

9 (10)

 

62 (78)

18 (23)

 

65 (81)

15 (19)

 

69 (78)

20 (22)

 

Race/ethnicity

[N = 141]

 

[N = 131]

 

[N = 131]

 

[N = 145]

 

 Black

19 (79)

5 (21)

0.0228

18 (75)

6 (25)

0.5126

20 (83)

4 (17)

0.9225

16 (70)

7 (30)

0.6991

 White+Latino

97 (95)

5 (5)

 

78 (84)

15 (16)

 

80 (86)

13 (14)

 

82 (77)

24 (23)

 

 Others

13 (87)

2 (13)

 

11 (79)

3 (21)

 

12 (86)

2 (14)

 

12 (75)

4 (25)

 

Histologic type

[N = 141]

 

[N = 131]

 

[N = 131]

 

[N = 145]

 

 IDC

106 (91)

10 (9)

0.0737

85 (79)

22 (21)

0.0624

89 (83)

18 (17)

0.2508

87 (73)

33 (28)

0.1731

 ILC

17 (100)

0 (0)

 

16 (100)

0 (0)

 

16 (100)

0 (0)

 

16 (94)

1 (6)

 

 Metaplastic

3 (60)

2 (40)

 

3 (60)

2 (40)

 

4 (80)

1 (20)

 

4 (80)

1 (20)

 

 Mixed IDC/ILC

3 (100)

0 (0)

 

3 (100)

0 (0)

 

3 (100)

0 (0)

 

3 (100)

0 (0)

 

Histologic gradea

[N = 141]

 

[N = 131]

 

[N = 131]

 

[N = 145]

 

 1 + 2

68 (100)

0 (0)

0.0003

62 (95)

3 (5)

0.0001

62 (95)

3 (5)

0.0022

65 (88)

9 (12)

0.0008

 3

61 (84)

12 (16)

 

45 (68)

21 (32)

 

50 (76)

16 (24)

 

45 (63)

26 (37)

 

sTIL level

[N = 139]

 

[N = 131]

 

[N = 131]

 

NA

 

 < 10%

102 (97)

3 (3)

0.0002

89 (91)

9 (9)

< 0.0001

90 (92)

8 (8)

0.0006

   

 ≥ 10%

25 (74)

9 (26)

 

16 (52)

15 (48)

 

20 (65)

11 (35)

    

ER

[N = 141]

 

[N = 131]

 

[N = 131]

 

[N = 145]

 

 Negative

30 (77)

9 (23)

0.0005

20 (57)

15 (43)

< 0.0001

24 (69)

11 (31)

0.0019

22 (56)

17 (44)

0.0018

 Positive

99 (97)

3 (3)

 

87 (91)

9 (9)

 

88 (92)

8 (8)

 

88 (83)

18 (17)

 

PR

[N = 141]

 

[N = 131]

 

[N = 131]

 

[N = 145]

 

 Negative

48 (83)

10 (17)

0.0037

34 (67)

17 (33)

0.0009

39 (76)

12 (24)

0.0236

36 (62)

22 (38)

0.0026

 Positive

81 (98)

2 (2)

 

73 (91)

7 (9)

 

73 (91)

7 (9)

 

74 (85)

13 (15)

 

HER2

[N = 141]

 

[N = 131]

 

[N = 131]

 

[N = 145]

 

 Negative

118 (91)

12 (9)

0.5987

98(81)

23 (19)

0.6881

103 (85)

18 (15)

1

99 (75)

33 (25)

0.7344

 Positive

11 (100)

0 (0)

 

9(90)

1 (10)

 

9 (90)

1 (10)

 

11 (85)

2 (15)

 

TNBC

[N = 141]

 

[N = 131]

 

[N = 131]

 

[N = 145]

 

 No

101 (97)

3 (3)

0.0003

88 (91)

9 (9)

< 0.0001

89 (92)

8 (8)

0.0014

90 (83)

18 (17)

0.0007

 Yes

28 (76)

9 (24)

 

19 (56)

15 (44)

 

23 (68)

11 (32)

 

20 (54)

17 (46)

 

Receptor group

[N = 141]

 

[N = 131]

 

[N = 131]

 

[N = 145]

 

 ER/PR pos

90 (97)

3 (3)

0.0012

79 (91)

8 (9)

0.0001

80 (92)

7 (8)

0.0038

79 (83)

16 (17)

0.0023

 HER2

11 (100)

0 (0)

 

9 (90)

1 (10)

 

9 (90)

1 (10)

 

11 (85)

2 (15)

 

 TNBC

28 (76)

9 (24)

 

19 (56)

15 (44)

 

23 (68)

11 (32)

 

20 (54)

17 (46)

 

Tumor size

[N = 141]

 

[N = 131]

 

[N = 131]

 

[N = 145]

 

 ≤ 2 cm

26 (84)

5 (16)

0.2433

19 (73)

7 (27)

0.4286

20 (77)

6 (23)

0.3765

21 (62)

13 (38)

0.049

 > 2 to 5 cm

54 (93)

4 (7)

 

49 (84)

9 (16)

 

51 (88)

7 (12)

 

43 (75)

14 (25)

 

 > 5 cm

49 (94)

3 (6)

 

39 (83)

8 (17)

 

41 (87)

6 (13)

 

46 (85)

8 (15)

 

ypN

[N = 141]

 

[N = 131]

 

[N = 131]

 

[N = 145]

 

 (y)pN0

39 (85)

7 (15)

0.0921

33 (77)

10 (23)

0.6247

36 (84)

7 (16)

0.9424

35 (74)

12 (26)

0.3048

 (y)pN1

45 (96)

2 (4)

 

36 (84)

7 (16)

 

36 (84)

7 (16)

 

37 (74)

13 (26)

 

 (y)pN2

22 (88)

3 (12)

 

19 (79)

5 (21)

 

21 (88)

3 (13)

 

18 (69)

8 (31)

 

 (y)pN3

23 (100)

0 (0)

 

19 (90)

2 (10)

 

19 (90)

2 (10)

 

20 (91)

2 (9)

 

pM

[N = 141]

 

[N = 131]

 

[N = 131]

 

[N = 145]

 

 0

119 (91)

12 (9)

1

101 (82)

22 (18)

0.6382

106 (86)

17 (14)

0.3272

100 (74)

35 (26)

0.1184

 1

10 (100)

0 (0)

 

6 (75)

2 (25)

 

6 (75)

2 (25)

 

10 (100)

0 (0)

 

RCB category

[N = 140]

 

[N = 130]

 

[N = 130]

 

[N = 144]

 

 I

4 (80)

1 (20)

0.5155

3 (75)

1 (25)

0.4125

3 (75)

1 (25)

0.2473

5 (83)

1 (17)

0.9425

 II

63 (91)

6 (9)

 

54 (86)

9 (14)

 

57 (90)

6 (10)

 

56 (77)

17 (23)

 

 III

61 (92)

5 (8)

 

49 (78)

14 (22)

 

51 (81)

12 (19)

 

48 (74)

17 (26)

 
  1. aHistologic grade for post-treatment tumors was based on pre-treatment grade
  2. IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, sTIL stromal tumor infiltrating lymphocytes, ER estrogen receptor, PR progesterone receptor, TNBC triple-negative breast cancer, pos positive, RCB residual cancer burden
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us